Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases.

Riva N, Molina M, Cornaló BL, Salvador MV, Savransky A, Tenembaum S, Katsicas MM, Monteverde M, Cáceres Guido P, Rousseau M, Staciuk R, González Correas A, Zubizarreta P, Imventarza O, Lagomarsino E, Spitzer E, Tinelli M, Schaiquevich P

Open source

DOI: 10.3389/fphar.2021.785770
Published: 2021
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2021.785770,
  title = {Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases.},
  author = {Riva N and Molina M and Cornaló BL and Salvador MV and Savransky A and Tenembaum S and Katsicas MM and Monteverde M and Cáceres Guido P and Rousseau M and Staciuk R and González Correas A and Zubizarreta P and Imventarza O and Lagomarsino E and Spitzer E and Tinelli M and Schaiquevich P},
  year = {2021},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2021.785770},
  url = {https://doi.org/10.3389/fphar.2021.785770}
}

RIS

TY  - JOUR
TI  - Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases.
AU  - Riva N
AU  - Molina M
AU  - Cornaló BL
AU  - Salvador MV
AU  - Savransky A
AU  - Tenembaum S
AU  - Katsicas MM
AU  - Monteverde M
AU  - Cáceres Guido P
AU  - Rousseau M
AU  - Staciuk R
AU  - González Correas A
AU  - Zubizarreta P
AU  - Imventarza O
AU  - Lagomarsino E
AU  - Spitzer E
AU  - Tinelli M
AU  - Schaiquevich P
PY  - 2021
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2021.785770
UR  - https://doi.org/10.3389/fphar.2021.785770
ER  -

APA

N, R., M, M., BL, C., MV, S., A, S., S, T., MM, K., M, M., P, C. G., M, R., R, S., A, G. C., P, Z., O, I., E, L., E, S., M, T., & P, S. (2021). Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2021.785770

Source records

pubmed · retrieved 2026-09-26T16:21:14.387Z
europe-pmc · retrieved 2026-09-26T16:21:14.402Z
doaj · retrieved 2026-09-26T16:21:14.404Z